Histone deacetylase inhibitor
| Histone deacetylase inhibitor | |
|---|---|
| Drug class | |
Vorinostat (SAHA; Zolinza), the first-approved and most-widely-known HDAC inhibitor. | |
| Class identifiers | |
| Synonyms | HDAC inhibitor; HDACi; HDI |
| Mechanism of action | Histone deacetylase inhibition |
| Biological target | Histone deacetylases (HDACs) |
| Chemical class | Various |
| Legal status | |
| In Wikidata | |
Histone deacetylase inhibitors (HDAC inhibitors, HDACi, HDIs) are chemical compounds that inhibit histone deacetylases. Since deacetylation of histones produces transcriptionally silenced heterochromatin, HDIs can render chromatin more transcriptionally active and induce epigenomic changes.
HDIs have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics, such as valproic acid. Since at least 2003 they have been investigated as possible treatments for cancers, parasitic and inflammatory diseases.